Skip to main content
Premium Trial:

Request an Annual Quote

Amersham and Bayer to Develop, Commercialize HIV Assays; FDA OK Sought

NEW YORK, Feb. 16 (GenomeWeb News) - Amersham and Bayer's diagnostics division plan to co-develop assays and instrumentation for sequencing HIV and other infectious disease-causing pathogens, the companies said today.


Terms of the exclusive partnership call for Amersham to supply a modified version of its existing MegaBACE gene sequencer, and for Bayer to develop sequencing assay applications for the tool. Bayer will also buy Amersham's reagents and other consumables for these and "future assays," the companies said.


Amersham and Bayer plan to seek USregulatory approval for the instrument and assays. It was not immediately clear when the companies expect to commercialize the instrument or the assays.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.